SYSTEM, METHOD AND APPLICATIONS INVOLVING IDENTIFICATION OF BIOLOGICAL CIRCUITS SUCH AS NEUROLOGICAL CHARACTERISTICS
Various aspects are directed to systems and methods for assessing neural activity of a neural region having multiple subfields. In certain embodiments, a method includes evoking a cellular electrical response in at least one subfield due to neural activity in the neural region, capturing image data of the electrical response at a level sufficiently detailed in space and time to differentiate between polarization-based events of two respective portions of the subfield, and then assessing neural activity by correlating space and time information, from the captured data, for the two respective portions of the sub-field. Other more specific aspects of the invention involve different preparation and neural stimulation approaches which can vary depending on the application.
This patent document claims the benefit, under 35 U.S.C. §119(e), of U.S. Provisional Patent Application Ser. No. 60/901,178, entitled System, Method and Applications Involving Identification of Neurological Characteristics and filed on Feb. 14, 2007; this patent application, including the Appendix therein, is fully incorporated herein by reference.
FIELD OF THE INVENTIONThe present invention relates generally to imaging systems and methods, and more particularly to imaging of biological networks.
BACKGROUNDUnderstanding the complexities of biological tissue and its electrical behavior continues to be an area of ongoing research and study. For example, a major challenge facing psychiatry is the lack of understanding of the neuronal network changes that underlie clinical depression and recovery. The hippocampus is hypothesized to play a central role in both depression pathophysiology and treatment response, but the underlying local network dynamics are not understood, with studies yielding apparently contradictory findings.
Development of new treatments for psychiatric disorders is hindered by an almost complete lack of information on how maladaptive neural physiology may give rise to affective phenotypes. For this reason, identification of a neurophysiological final common pathway linked to the etiology of a psychiatric disease could revolutionize understanding and guide clinical development of novel treatments. In depression, a leading cause of disability that affects an estimated 121 million people worldwide, the current widely-used medications are often effective in reducing symptoms and can promote remission, but treatment-resistance to first-line antidepressants like the selective serotonin reuptake inhibitors (SSRIs, such as fluoxetine and paroxetine) occurs in up to 50% of patients. Well-known medication side effects further complicate compliance and recovery, pointing to the need for new classes of treatment. Development of new classes of treatment is severely constrained by the incomplete understanding of the multifactorial biological etiology of depression, which involves genetic predisposition, epigenetic and developmental alterations, and adverse life events including chronic or acute stress. If many of these different etiological factors are expressed behaviorally through final common neurophysiological features, identification of these putative endophenotypes could not only provide a basis for understanding of the disease but also enable rapid development of novel selective classes of antidepressant treatments.
Candidate neural structures pertinent to depression physiology have been identified in part by using structural and functional imaging. Human fMRI studies have demonstrated altered blood flow associated with depression in several brain regions, including specific components of the emotion-regulating limbic circuitry. In particular, the hippocampus has received considerable attention as an integral component of the limbic system that communicates directly with and drives other brain regions implicated in depression, such as the prefrontal cortex, hypothalamic-pituitary-adrenal (HPA) axis, and reward centers. A substantial body of work favors the concept that the hippocampus is hyperactive in depression.
PET imaging has been used in depressed patients to implicate overactive excitatory pathways radiating from the hippocampus to downstream cortical regions (e.g., to Cg25) which is thought to be overactive in depression, and to orbitofrontal cortex), and furthermore found that fluoxetine-induced reduction in hippocampal activity was tightly linked to successful clinical response. Meta-analysis of functional brain imaging in medication treatment of depression indicated that changes in downstream cortical regions are delayed until specific adaptive changes occur in the source of primary afferent inputs, e.g., the hippocampus. This work showed that the hippocampus is a “primary site of action” for major antidepressants and a key initiator of successful response to antidepressant treatment. Complicating this picture, however, is evidence suggesting reduced hippocampal activity in depression, including reduced hippocampal size in clinical depression, the fact that excitatory hippocampal neurons display atrophy and death due to chronic stress and stress hormone exposure, and the observation that antidepressant-induced production of presumed excitatory neurons in the dentate gyrus of the hippocampal formation is linked to behavioral efficacy.
SUMMARYAspects of the present invention involve the implementation of new optical technologies that allow sufficient spatial (pm) and temporal resolution (ms) of electrical activity in distinct neural circuits.
Consistent with one embodiment of the present invention, a method is implemented for assessing neural activity in a neural region having multiple subfields. An electrical response is evoked in at least one subfield due to neural activity in the neural region. Image data of the electrical response is captured at a level sufficiently detailed in space and time to differentiate between polarization-based events of two respective portions of the subfield. Neural activity is assessed by correlating space and time information, from the captured data, for the two respective portions of the sub-field.
Consistent with one embodiment of the present invention, a method is implemented for assessing neural activity in a neuronal network that includes first and second portions electrically related to one another. The neuronal network is stained with a voltage sensitive dye. The first portion of the neuronal network is stimulated. Responsive to the stimulation, image data is captured that results from the voltage sensitive dye and neural activity in the first portion. The image data is processed to assess neural activity indicative of a disorder.
Consistent with one embodiment of the present invention, a system is implemented for determining neural activity in a neural region having multiple subfields. A preparation arrangement prepares the neural region for imaging A stimulation arrangement stimulates at least one subfield in the neural region. An imaging device for captures image data resulting from stimulation of the neural region, wherein the image data is captured at a level sufficiently detailed in space and time to differentiate between polarization-based events of two respective portions of the subfield. A processor assesses neural activity by correlating space and time information, from the captured data, for the two respective portions of the sub-field.
Consistent with one embodiment of the present invention, an arrangement is implemented for use in a system for determining neural activity in a neural region having multiple subfields, the system including a preparation arrangement for preparing the neural region for imaging, a stimulation arrangement for stimulating at least one subfield in the neural region, and an imaging device capable of capturing image data resulting from stimulation of the neural region. The arrangement includes a processor programmed and adapted to process image data captured at a level sufficiently detailed in space and time to differentiate between polarization-based events of two respective portions of the subfield, to assess neural activity by correlating space and time information, from the captured data, for the two respective portions of the sub-field.
Consistent with one embodiment of the present invention, storage medium for use in a system for determining neural activity in a neural region having multiple subfields, the system including a preparation arrangement for preparing the neural region for imaging, a stimulation arrangement for stimulating at least one subfield in the neural region, and an imaging device capable of capturing image data resulting from stimulation of the neural region, a storage medium storing computer-executable data which, when executed by a computer arrangement, cause the computer arrangement to perform steps. A first step involves processing image data captured at a level sufficiently detailed in space and time to differentiate between polarization-based events of two respective portions of the subfield. A second step involves assessing neural activity by correlating space and time information, from the captured data, for the two respective portions of the sub-field.
The above summary of the present invention is not intended to describe each illustrated embodiment or every implementation of the present invention. The figures and detailed description that follow more particularly exemplify these embodiments.
The invention may be understood in consideration of the detailed description of various embodiments of the invention that follows in connection with the accompanying drawings in which:
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
DETAILED DESCRIPTIONThe present invention is believed to be applicable to a variety of different types of processes, devices and arrangements involving imaging excitable tissue. Aspects of the present invention have been found to be particularly advantageous in applications benefitting from or involving assessment of neural activity. While the present invention is not necessarily so limited, various aspects of the invention may be appreciated through a discussion of examples using this context.
Embodiments of the present invention are directed to methods, systems and devices for assessing electrical activity of a neural region. Aspects of the invention allow for assessment of such electrical activity with high temporal and spatial precision. High-speed and high-resolution imaging devices capture data responsive to the electrical activity. Specialized processing techniques are used to assess the electrical activity by correlating time and phase information about the captured data.
In connection with various embodiments of the present invention, a neural region is targeted for assessment of neural activity. The neural region has subfields or local networks consisting of a relatively small number of neural cell groups. Image capture of a subfield is performed so as to provide sufficient detail in space and time to differentiate between polarization events (i.e., depolarization events or hyperpolarization events) of respective portions of the subfield. These portions can range from a single neuron to a small group of neurons sufficient to distinguish individual polarization events within the portions of the subfield. In a particular instance, the respective portions represent one or more captured image pixels. In one instance, the spatial detail is on the order of millimeters (e.g., sub centimeter). In another instance, the spatial detail is on the order of micrometers (e.g., sub millimeter). The temporal detail can range from around a half second to a few milliseconds or even faster.
One embodiment of the present invention involves the use of spatial and temporal correlation techniques to assess the neural activity of subfields. These techniques are designed to scale with the precision of the image capture technology allowing for use with a wide variety of current and future image capture technologies.
Embodiments of the present invention use voltage sensitive dye imaging (VSDI) to probe quantitatively the dynamics of other neural networks following the induction, diagnosis or treatment of medical states or diseases. One such embodiment uses VSDI to probe quantitatively the differences in network activity due to various factors including, but not limited to, those differences underlying psychiatric disease and treatment.
Other embodiments of the present invention use other imaging techniques, such as infrared imaging, near-infrared imaging or optical topography. Such techniques involve the capture of image data relative to the properties of blood within the neural region (e.g., hemoglobin concentrations). Activity within the neural region results in rapid changes to localized blood volume. The captured image data includes data regarding the properties of the blood within specific regions of the neural region. This data is obtained through a determination of optical absorption coefficients.
A specific embodiment of the present invention uses a VSDI process to assess correlations between stimuli and resulting electrical responses. Stimuli elicit responses from the neural network. Voltage responsive dyes allow images of the responses to be captured using an imaging device. Correlation techniques are implemented to match the data from the imaging device to the stimuli. For instance, delays are inherently present between the application of the stimuli and the capturing of the image data. Factors in the delay include, but are not limited to, propagation delay through the neural network, delay in the voltage-sensitive dye response, imaging device delays and processing delays. In a particular embodiment, the stimuli profile is compared to the image data with respect to time/phase. The comparison can be accomplished by implementing a pixel-by-pixel correlation between the stimulus and the pixel response. The pixel response can be determined as the amount of change from one frame to the next.
One embodiment of the present invention uses voltage sensitive dye imaging (VSDI) to probe quantitatively the dynamics of neural networks (e.g., hippocampal) with millisecond resolution following bidirectional affective state modulation (including both induction and treatment of depressed-like states). It has been found that a single measure of high-speed neurophysiological activity-the evoked spread of activity through the dentate gyms of the hippocampal formation, relative to that in CA1, accounts for bidirectional changes in animal behavior in a manner that is independent of the underlying mechanism of action of the affective state modulators. These high-speed imaging results define a network-level endophenotype for depression unifying disparate findings in the literature, and demonstrate a tractable approach to the understanding and treatment of neural substrates of psychiatric disease.
While much of the discussion herein is directed to VSDI and/or optical tomography, the invention is not so limited. To the contrary the various embodiments, for example, the processing and correlations techniques, are applicable to any number of different data capture techniques. For instance, the processing and correlation techniques can be applied to any data set that contains temporal and spatial information having sufficient granularity and precision.
In an example of one such an alternative embodiment, a slice of brain is obtained which includes representative samples of the prefrontal cortex, the dorsolateral prefrontal cortex, and the subgenual cingulate. This block of tissue is treated with a calcium dye. Various calcium dyes are able to resolve ion flux on a cellular scale with microsecond precision. Using such dyes, the activity of these regions can be used to assess the neural activity of various regions and their interconnections. For example, an assessment could be made as to whether the dorsolateral prefrontal cortex has a direct correlation with the activity of the prefrontal cortex, and inverse relationship with the activity of the subgenual cingulate cells. In the case of depression, this may reach a steady state in which the subgenual cingulate is relatively overactive as compared with the prefrontal cortex. In the context of this experimental paradigm, candidate drugs may be tried with respect to their differential effect on these regions within the sample. Ideal drugs for example might serve single targeted neurophysiological roles, without creating additional neurophysiological effects which are competitive to the therapeutic goal. For example, a drug which succeeds in lowering activity levels in the subgenual cingulate without lowering activity in the prefrontal cortex as well may be preferable to one which attempts to lower activity generically in both. Also in the context of such an embodiment, ideal locations for neuromodulation of specific sites within the circuit may be identified, with and without the benefit of synergistic medications.
Readout or image capture of the physiological activity of the neural network can be accomplished by a variety of techniques including calcium imaging, biochemical imaging and infrared imaging. PET and fMRI may also be applicable, albeit at lower spatial and temporal resolutions.
Stimulating the circuit may be accomplished with a variety of means that influence cellular activity, including application of drugs, magnetic fields, electrical current, optical (including opto-genetic) stimulation, ultrasound thermal and radiation methods as are known in the art.
Depending on the readout source, data may be captured for example with a CCD camera, or as a digital matrix of sensor readings obtained from a sensor grid, or serially positioned sensors. Processing resultant readout data by correlating activity level of cell types may be accomplished with computer software, for image analysis applications such as Image J (U.S. National Institutes of Health, Image J consortium). Providing processed correlation results to the user may be provided through screen displays, printed and transmitted data.
The various methods and systems discussed herein (including those discussed in connection with the flow diagram of
In order to assess the network activity a number of different methods can be used to evoke a response in the target neural region. A first example involves applying direct electrical stimulation to a portion of the network. This can be accomplished using, for example, patch clamping or other electrical probe devices and methods. Another example involves the use of various electromagnetic (EM) waves to evoke the desired response. Various different EM wave sources are possible depending upon the type of EM wave. A first example includes optical (visible or near-visible) EM waves from a number of sources, such as light-emitting-diodes (LEDs) or lasers. Another example of EM-type stimulus includes gamma rays or X-rays. Additionally, a response can be evoked using physical stimulus, such as physical perturbation provided by ultra-sound. Ultra-sound can also be used to evoke a response by heating the target neural region. Yet another mechanism for evoking a response includes the use of a pharmacological or chemical agent to affect the firing rate of the neural region.
For applications involving a live subject, in addition to the stimulus discussed above, a response can be evoked by providing any number of external stimuli to the subject including, but not limited to, physical, mental and chemical stimuli.
A specific embodiment of the present invention can also be implemented by relying upon intrinsic neural activity. In this context, evoking a response involves providing conditions for the neural network that are conducive to producing the intrinsic neural activity. For example, the cardiac conduction system includes the intrinsic firing of both the SA and AV nodes. Intrinsic network activity from either or both of these nodes can be assessed by providing proper conditions for the neural networks. Additionally, the effects of various treatments (e.g., drugs or otherwise) on the intrinsic network activity can also be assessed by first applying the treatments and assessing the resulting network activity. Another possible implementation for intrinsic neural activity is to correlate interdependencies between areas within a subfield or between different subfields.
Test sample 108 includes a neural network that is under test. In a specific example, the neural network is representative of one or more specific subfields of the brain. The effects of a particular drug or treatment may be monitored for more than just average activity over time. Using an embodiment of the present invention, the effect of the treatment with respect to specific activity patterns within a subfield can be monitored and assessed.
In one instance, the indicator fluoresces in response to light from optical source 106. Optical control 104 may also include a reconfigurable readout, so that as different light-activated membrane potential switches (LAMPS) and different light-emitting indicators of cellular activity (LEIAs) are used, the same control system can be readily adapted to each paradigm. Optical detector 109 produces a signal responsive to such florescence, and optical control 104 receives the produced signal. The optical control 104 stores data obtained from the signal in database 102. The information stored includes spatial and temporal data regarding the electrical activity of the test samples 108. Other information may include factors such as the intensity, duration and wavelength of the detected light. In a particular instance, the stored data can be compared against baseline data, where the baseline data corresponds to data recorded prior to the introduction of the drug to the test sample 108. In another instance, optical source 106 may vary the intensity, duration or other parameters related to the control of optical source 106. These and other parameters may be stored in database 102. These parameters are then used to assess the network activity.
It should be apparent that optical source 106 may be implemented using a single light source, such as a light-emitting diode (LED), or using several light sources. Similarly, optical detector 109 may use one or more detectors and database 102 may be implemented using any number of suitable storage devices.
Dichroic mirror 170 allows for upward reflection of both the wavelength required to stimulate the optical gating of the membrane (e.g., blue for ChR2), and the wavelength required by any LEIA used (e.g., ultraviolet for FURA-2). This dichroic mirror may be arranged to allow passage of the output spectrum of the LEIA (e.g., blue-green for FURA-2) with minimal reflection or absorption.
For further details regarding drug screening processes, systems and devices, including those directed to a high-throughput screening environment, such as array-based optical screening system, reference can be made to U.S. patent application Ser. No. 60/996,116, to Zhang et al., filed on Aug. 10, 2007 and entitled “Cell Line for Optically-Based Screening of Ion Channel Modulators”.
The hippocampus is an example target for various embodiments of the invention, as it is not only a central component of limbic neural circuitry implicated in depression and drug response, but also the gateway through which multimodal sensory information is stored and flows to the limbic system. Models of hippocampal function from the memory literature can be used as a framework for understanding how the hippocampus may mediate affective responses. These models assign fundamentally different roles to the associative (e.g., dentate gyrus or DG) and output (CA1) subfields of the hippocampal formation in spatial and temporal memory processing. For example, the CA1 region is often conceptualized as a comparator of signals received directly from the cortex, to signals received from DG (by way of CA3), that then outputs this difference or “error” signal to downstream cortical and subcortical structures. The DG and CA1 local networks not only operate very differently, but neurogenesis occurs only in the DG; moreover, neuromodulators and stress hormones each can yield distinct effects on the DG and CA1 subfields. In light of these differences, the disparate clinical findings regarding hypoactivity or hyperactivity of the hippocampal formation in depression could in principle be reconciled with technology capable of separately resolving electrical activity of the associative (e.g., DG) and output (CA1) local circuits in behaviorally relevant paradigms. An example application of VSDI imaging consistent with an embodiment of the present invention is used to address such disparate clinical findings. While the invention is not so limited, the discussion of such a specific application can be useful to an understanding of the present invention.
In probing the neurobiology of psychiatric disorders, rodent models have proven useful in isolating key features that may underlie disease etiology. Models of depression include paradigms based on stress, learned helplessness, neurological lesion, and/or genetic manipulation. In particular, the chronic mild stress (CMS) paradigm has excellent predictive, face and constructs validities, models core symptoms, and is considered to be an ethologically relevant model of depression. Although molecular, synaptic, cellular, and anatomic markers have been linked to depression or antidepressants in several of these animal models of disease, a neurophysiological endophenotype of depression has yet to be identified that captures relevant changes in network activity with high spatiotemporal resolution.
Applications of the present invention implement VSDI technology as a powerful, quantitative tool to probe the alterations in network activity to determine their contributions to neuropsychiatric disease. For example, given the primary role of the hippocampus in depression and its treatment, VSDI was used to observe hippocampal activity directly with high spatial and temporal resolution in rodent models of depression and antidepressant treatment. The parameters of hippocampal activity measured by VSDI reliably predict behavioral performance on a forced swim test following combinations of CMS and chronic antidepressant treatment. Specifically, CMS significantly reduces activity in the DG and increases activity in CA1; moreover, chronic antidepressant treatment induces opposite effects, confirming the initial hypotheses. Together, these results identify the activity of the DG relative to CA1 as a neurophysiological endophenotype of depression that spans responses to distinct classes of antidepressants, combinations of stress exposure and antidepressant treatment, and multiple mechanisms of action on the cellular level. The DG-CA1 relative activity, a subfield-resolved measure of high-speed hippocampal electrical activity, unifies contradictory and disparate findings in the field and may represent a common pathway through which mechanistically diverse processes contribute to depression and its treatment.
To use high-speed VSDI to explore neuronal network activity changes in psychiatric disease models, experimental analysis methods were developed to extract reliable quantitative features from the imaging data across animals. A specific implementation of one embodiment of the present invention was used to probe the DG-CA1 activity in depressed mice. A description of the figures related to this implementation follows, with specific details of the implementation provided thereafter.
While mean signal amplitude was not modulated by fluoxetine or irradiation treatment (left; ANOVA, F3,179=2.390, n=37−60 evoked slice responses per group), the active network area was modulated similarly to the total activity measure (right, ANOVA, F3,180=5.502, n=37−60 evoked slice responses per group, *p<0.05;
VSDI with a digital camera system optimized for high speed, sensitivity, and resolution was used to observe the activity of intact networks within acute horizontal slices prepared from the ventral hippocampus of adult, female rats (
Thus, the signal quality, consistency, and linear response of the data showed the usefulness of this high-speed VSDI technology for quantifying abnormalities of intact network dynamics in CNS disease.
To explore hippocampal network activity changes induced in a depression model, a 7-week chronic mild stress (CMS) paradigm was used to elicit an ethologically relevant, depressed-like state in adult, female rats (
To determine the network activity changes associated with these induced depression-related behavioral phenotypes, acute hippocampal slices were generated from the same animals for high-speed VSDI. Both the DG and CA1 networks were specifically probed for the reasons described above, anticipating that there would likely be different effects in each local network that might nonetheless each be linked to the behavioral phenotype. For both of these local networks, it was found that the total activity measure is a reliable and quantitative indicator of evoked network activity that is linear with the applied stimulus strength across animals (
The CA1 aspect of this pattern is compatible with previous work linking depression to elevated driving of pathways emerging from the hippocampus, and the DG aspect is consistent with data linking depression to reduced intra-hippocampal formation activity. Together this data introduces the concept of an activity mismatch between early associative and late output stages in hippocampal processing. To validate this novel measure, the network-level responses were probed in slices from the antidepressant (fluoxetine, imipramine) or typical antipsychotic (haloperidol) treated animals. Precisely the opposite pattern of network activity was found in antidepressant-treated animals, which showed increased activity in DG (
To assess the generality of the results over conditions that model the clinical use of antidepressants to treat depressed states, animals were exposed to CMS for five weeks to induce a depressed-like state and then administered fluoxetine chronically during the last two weeks of the protocol to reverse the effects of CMS (
Behavioral results confirmed the induction of a depressed-like state in CMS-treated animals, and also the efficacy of fluoxetine in reversing the behavioral effects of CMS (
In the same experiment, open field tests (OFT) were also conducted to measure anxiety-related behavior. The relationship between this anxiety measure and network dynamics responses was investigated in order to determine the specificity of the identified network phenotype for the depressed-like state measurement of FST performance (
Next changes in neurogenesis associated with these bidirectional changes in behavior and network activity were probed for, to determine if the network dynamics metric depends chiefly on a single biological mechanism or instead retains its validity across fundamentally different mechanisms that may underlie CMS and antidepressant responses. Neurogenesis appears to be strongly linked to antidepressant effects on the novelty-suppressed feeding task, but has not been clearly implicated in depression-related behavioral measures like the FST or in depression induction involving chronic mild stress. However, acute and severe stress can inhibit neurogenesis, suggesting that altered neurogenesis in some settings could contribute to the etiology of depression. To directly investigate whether the network and behavioral effects of both CMS and antidepressant treatment could depend in part on a common underlying neurogenesis mechanism, bromodeoxyuridine (BrdU) was administered to label dividing cells during the last week of treatment in the experiment described in connection with
To definitively demonstrate changes or lack thereof in neurogenesis, the BrdU+ cells were phenotyped using the mature neuronal marker NeuN and the immature neuronal marker Doublecortin (Dcx;
To further probe the contribution of neurogenesis to the depression-related behavioral and physiological effects of antidepressant treatment, a novel protocol was developed to isolate long-term effects of a temporally defined cohort of fluoxetine-induced newborn neurons. This paradigm incorporates one week of chronic fluoxetine treatment to trigger a burst of neurogenesis, followed by a three week delay period to permit both behavioral testing in a drug-free state and functional integration of neurons born during antidepressant administration (the newborn-neuron specific antidepressant protocol, NNS;
To quantify effects of the NNS antidepressant treatment on the number of newborn cells and to confirm the selective reduction of hippocampal neurogenesis by irradiation, BrdU was injected during the week of drug treatment and conducted stereological counts as described above. NNS-fluoxetine treatment increased the BrdUi cell density as expected, and irradiation considerably reduced the BrdU+ population (
These results suggest that while neurogenesis can be important in eliciting behavioral and physiological effects of an antidepressant, it does not follow that changes in neurogenesis necessarily play a significant role in the etiology of the depressed state. Behaviorally effective CMS treatment did not decrease neurogenesis and ablation of hippocampal neurogenesis in control animals did not induce a depressed-like state (
Although it has been shown that hippocampal neurogenesis has an impact of antidepressant treatment on the DG network dynamics, it is not immediately obvious how a modest increase in neurogenesis could affect global network activity, especially with estimates that newborn neurons normally comprise only several percent of the DG population. To assess the ability of neurogenesis to implement changes in physiological properties of the whole network, two simple models were generated to study the effect of new neurons on activity propagation (
Dynamics of either model showed that networks with rare new neurons could recruit greatly increased numbers of neurons into activity, compared to networks with no new neurons (
Since the models demonstrate that adding small numbers of neurons can profoundly affect the spatial extent of activity spread, the experimental data was analyzed regarding features of the experimental VSDI signal itself to determine the contribution of altered signal area to the observed physiological effects of neurogenesis in the DG. The total activity measure derived from the VSDI signal is defined as the product of the area of the active region and the mean amplitude of the signal. No appreciable effect was found of antidepressant-induced neurogenesis on mean signal amplitude (
A combination of high-speed VSDI, structural analysis, and behavioral testing were employed to probe for depression-linked network abnormalities. First, fast VSD imaging and analysis technology was developed to generate high spatiotemporal-resolution maps of neuronal activity (
It is important to consider how known etiologies of, and treatments for, major depression are likely to modulate the DG-CA1 relative activity. Considering etiology first, depression-like behavior can be induced without reducing the rate of neurogenesis (
Furthermore, it is certainly possible that acute and severe stress, which can create vulnerability to depression, could reduce new neuron production in human beings as in animals and impair circuit plasticity. Regarding treatments, since insertion of new neurons into the DG appears to be sufficient to drive relevant network-dynamics changes, these data could account in part for the therapeutic effects of the large number of antidepressant treatments known to increase neurogenesis in animal models, including SSRI's, TCAs, electroconvulsive therapy, lithium, environmental enrichment, and exercise. While it is not formally known if the antidepressant-induced newborn neurons in the DG are excitatory or inhibitory themselves or which cell types their axons target, addition of these neurons to the circuit appears to increase total evoked DG network activity (
Some antidepressant treatments clearly do not directly target the hippocampus, such as deep brain stimulation (DBS) which can be targeted to Cg25 or accumbens. However, DBS is known to reduce activity in Cg25 which receives important excitatory projections from the hippocampus, suggesting that subgenual DBS can intervene downstream of an overactive CA1. It had not been known how to unify into a single model the hippocampal atrophy seen in depression with the increase in excitatory driving of cortex from hippocampus associated with clinical depression. These results suggest that the increased activation in the subgenual cingulate during depression could result in part from increased CA1 activity, while reduced intrinsic hippocampal formation function in depression would agree well with the decreased activity of the DG.
In an interesting parallel to the observation that the ratio of DG to CA1 activity in the ventral hippocampal formation predicts mood-related behaviors, dorsal hippocampal memory storage models have described roles for DG and CA1 that involve competitive and comparative interactions in the two local networks. One class of models suggests that CA1 functions in retrieval and transmission to cortex of stored episodic memory, and that the DG gates this retrieval based on contextual information. Other models suggest that the DG, in combination with CA3, generates a predictive signal that is sent to CA1, where this prediction is compared to cortically driven signals representing sensory reality in order to detect unexpected stimuli; the resulting difference signal is then transmitted to cortex. Mood-related hippocampal dysfunction has not been as well modeled but is thought to underlie aspects of the cognitive symptomatology of depression including hopelessness, which can manifest clinically as the inability to foresee or navigate a reasonable and hopeful plan within the context of the patient's environment. Antidepressant treatment that increases the relative activity of the DG to CA1 could drive the hippocampal comparative output in the direction of DG-derived predictive signals, signaling an increase in the ability of the hippocampal formation to model, predict, and plan for the future utilizing contextual information. In contrast, decreasing the, activity of DG relative to CA1, as observed in the depressed-like state, would imply impaired recognition and predictive roles of the DG and an inaccurate mismatch signal from CA1 driving cortical structures like Cg25. Whether this signal is interpreted with negative valence (signaling a poor model of the world and therefore hopelessness) or positive valence would depend on concomitant reward pathway activity involving distributed systems in the amygdala, accumbens and mesolimbic dopamine projections.
Identification of this hippocampal neurophysiological endophenotype serves as a starting point in mapping the network-level changes in other brain regions implicated in depression, such as the prefrontal and cingulate cortices, amygdala, basal ganglia, and reward centers. While these other brain regions are undoubtedly involved in depression physiology, the ability of this hippocampal measure to convey information regarding the animal's behavioral state supports the emerging hypothesis that the hippocampus plays a primary role in mood regulation, in addition to its accepted role in learning and memory. High-speed, whole network analysis with VSDI is clearly indicated to probe changes in other implicated brain regions, in models of depression and other neuropsychiatric disorders. Using the techniques and methods discussed herein it should be apparent that more detailed models of altered activity flow are possible and that this methodology can be extended to other depression models and treatment paradigms. This putative endophenotype is contemplated for use in screening for treatments that specifically and similarly modulate hippocampal dynamics. Depression and antidepressant-induced changes to neural circuitry can be monitored using the techniques and systems discussed herein and may be useful for achieving a quantitative understanding of the depressed brain.
Accordingly, the various methods and systems described herein can be used for the treatment of depressed states in patients. In one such instance, the effectiveness of drugs and other treatment techniques can be quantitatively measured and tailored to minimize unwanted side-effects. In another instance, the characteristics of the CA1 and DG in a patient can be used to make diagnosis of the patient's depressed state. Whether implemented in vitro on a neural network of a related specimen or in vivo on the neural network of the same subject, these approaches can be particularly useful for determining which patient treatments would be most effective.
Such a method need not be conducted in slices. For example, using infrared imaging, in which a high-resolution CCD camera is implanted next to the brain structure of interest, the brain circuits of a living organism can be scanned in real time, with areas of interest analyzed in accordance with the presently described method. As infrared tomography (from external to the body) advances in capabilities, it is anticipated that these methods will permit acquisition of data at sufficient temporal and spatial resolution so as to serve within the context of the present invention.
For further details regarding modeling depression through use of various embodiments of the present invention reference can be made to “High-Speed Imaging Reveals Neurophysiological Links to Behavior in an Animal Model of Depression” by Airan et al. (Science, Aug. 10, 2007, Vol. 317 pp. 819-823), which is fully incorporated herein by reference.
While the VSDI signals received in embodiments of the invention are robust and reliable, the known low signal to noise ratio can be compensated for using various design and analyses. In one such example, only evoked responses are considered so that stimulus/response cross-correlation analysis can be utilized to take advantage of the known response timing. Additionally, for proper cross-slice and animal comparison, an algorithm is used to automatically and efficiently extract relevant parameters of the signal (region of interest, mean amplitude, etc.) from the data. Peak response amplitude of −0.1% ΔF/F was sufficient for proper signal extraction.
The following algorithms provide an example implementation for use in analyzing the VSDI data collected according to the methods and systems described herein. To begin the analysis, the raw VSDI data were imported into a software application, such as MATLAB (Mathworks, Natick, Mass.). The data was represented as an initial reference frame (F), followed by each imaging data frame, which contained differential fluorescence values (ΔF). For each pixel and frame, the ΔF/F value was calculated. Each temporal frame was then spatially smoothed using a 3×3 pixel digital Gaussian kernel (σ=1):
During imaging, multiple individual sweeps (e.g., four sweeps) are recorded of activity responding to stimulation with each frequency and in each region. Following spatial averaging, these four sweeps were averaged frame by frame, producing one VSDI movie (
Where r[] is the pixel's response signal and s[] is the stimulation profile used during acquisition (
The maximum of the cross-correlation amplitude (max[Øsr[m]]), which measures the system's response to stimulation, was then found for each pixel, as well as the delay of this peak (phase=arg[max[Øsr[m]]). If there is an arbitrary software delay of the camera system used, the phase values at this stage are arbitrary with respect to the real latency of response to stimulation.
Timing of the response with respect to the stimulus can be calculated later using an absolute reference point inserted by closing a shutter during acquisition prior to stimulation.
To extract the region of interest, it is observed that pixels in this region tended to be clustered and of similar phase to one other (
To remove outlying values, the upper and lower 25% of the distribution was replaced by a padding (initially plus or minus 25 ms). The pixels with phases in this range were defined to be part of the region of interest. If the number of pixels in this region was too low (less than 3% of the total frame size), this suggested a relatively broad phase range of the true region of interest and the padding was incremented until this number of pixels was above an absolute threshold (3% of the frame size). The resultant pixels formed the initial calculated region of interest (
Upon defining this initial region of interest, median filtering with a 3×3 pixel window was completed to remove spurious pixels outside the region of interest, and morphological smoothing (first image-opening by 4 pixels and then image-closing by 6 pixels) was completed to close gaps existing within the region of interest. To remove any pixels outside the region of interest, the resulting pixel maps were manually cropped with the user blinded to treatment group producing the final, extracted region of interest (
After extracting the region of interest, the mean correlation amplitude of pixels within this region and the total area of the region of interest (as a percentage of frame size) were then calculated. The mean amplitude multiplied by this area (“total activity”) was the final statistic used to measure system response for the voltage sensitive dye imaging data. Even though voltage changes due to glia can be observed with voltage sensitive dyes, the total activity measures reported here likely indicate only neuronal responses to stimulation, as opposed to the slower responses of hippocampal glia that are not appreciably sensitive to AMPA and NMDA block especially given the short latency to peak of the VSDI traces (6.3+/−0.6ms for 2 Hz stimulations), the lack of summation of responses following 2 Hz stimulation, and the reliance of the signal on AMPA and NMDA transmission (
In one embodiment of the present invention, the aforementioned algorithms can be iteratively applied so as generate a large-scale image of general neural activity. This large-scale image can be more informative than less precise methods because the image is derived from precise temporal and spatial data obtained from a number of the relatively small portions of subfields.
Additionally, while asynchrony in the individual responses in principle could yield a modulation of the correlation amplitude relative to the absolute activity in the network, the phase values local to each pixel were tightly correlated and not observably patterned and no consistent effects on phase were noted between the various treatments. These results combined with short latency of the responses indicate that there is not a significant contribution of asynchronous responses to extracellular stimulation in these experiments. Furthermore, given the minimal role of the mean amplitude in modulating total activity (
Aspects of the present invention can be used in combination with a variety of neuron-directed applications, including those which are discussed in the related background articles cited above and listed herewith. For example, for detailed discussion of in vivo VSDI applications, reference may be made to “Spatiotemporal Dynamics of Sensory Responses in Layer 2/3 of Rat Barrel Cortex Measured In Vivo by Voltage-Sensitive Dye Imaging Combined with Whole-Cell Voltage Recordings and Neuron Reconstruction” (The Journal of euroscience, Feb. 15, 2003, 23(3) pp. 1298-1309), which is fully incorporated herein by reference. Another example that is specifically directed to hippocampal CA1 aspects is discussed in the article entitled “Hippocampal CA1 Circuitry Dynamically Gates Direct Cortical Inputs Preferentially at Theta Frequencies” (The Journal of Neuroscience, Oct. 19, 2005, 25(42) pp. 9567-9580), which is fully incorporated herein by reference.
Various applications of the invention can be applied to any disease where percolation of activity, excitation, inhibition, or the ratio of excitation to inhibition between two or more cell populations may be usefully addressed with imaging and processing techniques disclosed herein. For example, in Alzheimer's disease, the hippocampus and entorhinal cortex become diseased early. Mild cognitive impairment (MCI) may be a hallmark of this early AD process. Down Syndrome is manifested by a number of neurological abnormalities developed as a result of gene expression from an extra 21st chromosome. Among these are underdeveloped brain structures including the temporal lobe, and a nearly universal propensity for developing Alzheimer's disease. Autism, schizophrenia, bipolar disorder and many other conditions may be studied and improved treatments developed by identifying circuit-level endophenotypes as described in the present application, and using these as a well-circumscribed paradigm in which to target candidate treatments.
Various embodiments of the invention are useful to elucidate the role of one or more elements within a circuit. For example, one aspect involves assessing the interdependency (or independence) of areas of a subfield from the level of activity of areas of the subfield circuit. Quantitative analysis allows interdependencies to be identified and decoded.
Other embodiments of the invention can be used to elucidate the location of the activity of a drug within that circuit. For example, a drug may be added to the neural circuit, and the locations of activity change (relative to activity without the drug) are readout and recorded. These changes can be used to assess both primary sites of action, and downstream effects upon the greater circuit.
Another embodiment of the invention can be used to elucidate the effect of a drug on a given circuit. For example, specifically looking for fast acting/acute acting drugs, such as ketamine, for depression, by bath applying the drugs to find the right acute drug and drug dose that tunes activity in the desired manner in the high-throughput screening setting, thereby identifying drugs that act in days or hours rather than weeks/months
Other embodiments can be used to identify endophenotypes that have the high predictive value for a given disorder or to identify target locations for physical interventions including electrical, magnetic stimulation and ultrasound and radiation treatments.
The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Based on the above discussion and illustrations, those skilled in the art will readily recognize that various modifications and changes may be made to the present invention without strictly following the exemplary embodiments and applications illustrated and described herein. For instance, such changes may include uses for neurological characteristics other than depression, such as other diseases, disorders and even the study of normal activity. Other such changes include various in vivo imaging implementations. Such modifications and changes do not depart from the true spirit and scope of the present invention, which is set forth in the following claims.
Claims
1.-38. (canceled)
39. A system for assessing neural activity, the system comprising:
- a stimulator configured to evoke a cellular electrical response in at least one subfield of a neural tissue in a neural region having multiple subfields by stimulating neuronal cells of the neural region that express a light-activated ion channel and/or a light-activated ion pump protein;
- an imager configured to capture image data of the cellular electrical response at space and time limits of resolution that allow for differentiation between polarization-based events of two portions of the at least one subfield, wherein each of the two portions comprises a group of neurons; and
- a processor configured for assessing neural activity, wherein assessing neural activity comprises correlating space and time information, from the captured image data, for the two portions of the at least one subfield to produce correlation results.
40. The system according to claim 39, further comprising a composition comprising a nucleic acid encoding the light-activated ion channel and/or the light-activated ion pump protein.
41. The system according to claim 39, further comprising a composition for staining the neural tissue, wherein the composition comprises at least one of: a voltage sensitive dye, and a calcium sensitive dye.
42. The system according to claim 39, wherein the correlation results comprise a correlation between a signal strength of a stimulation profile and each pixel in the image data, and wherein the processor is further configured for:
- determining the correlation between the signal strength of the stimulation profile and each pixel in the image data;
- determining a cross-correlation amplitude for each pixel based on the determined correlation;
- determining a cross-correlation phase for each pixel based on the determined correlation;
- identifying areas of interest as a function of a spatial location of each pixel and the determined cross-correlations; and
- limiting pixel variations in the image data that are not in the identified areas of interest.
43. The system according to claim 39, wherein the processor is further configured for: assessing target locations for a treatment that includes a physical intervention.
44. The system according to claim 39, further comprising a computer arrangement comprising:
- the processor; and
- a storage medium storing computer-executable data, wherein, when the computer-executable data is executed by the processor, the processor assesses neural activity by correlating space and time information, from the captured data, for the two portions of the at least one subfield.
45. The system according to claim 39, wherein the processor is configured for comparing the correlation results with and without a treatment for the neural region, wherein the treatment is at least one of: a pharmacological chemical based substance, a nonchemical-based therapeutic treatment, a neural-invasive treatment, a neural-genesis treatment, and a neural-modulation treatment.
46. The system according to claim 39, wherein the processor is configured for assessing endophenotypes for a predictive value relative to a disorder.
47. The system according to claim 39, wherein assessing neural activity further comprises assessing a role of one or more subfields within a neural circuit.
48. The system according to claim 39, wherein neural activity is assessed relative to a depressed state of the neural region.
49. The system according to claim 39, wherein neural activity is assessed relative to one or more of: Alzheimer's disease, mild cognitive impairment, autism, bipolar disorder, schizophrenia, and Down Syndrome.
50. The system according to claim 39, wherein:
- the space limit of resolution is less than a centimeter;
- the time limit of resolution is less than 500 milliseconds; and
- the polarization-based events involve at least one of: depolarization events and hyperpolarization events.
51. The system according to claim 39, wherein the space limit of resolution is less than about a millimeter.
52. The system according to claim 39, wherein the subfields include dentate gyrus (DG) and CA1 subfields of the hippocampus.
53. The system according to claim 39, wherein the neural region is selected from the group consisting of hypothalamus, frontal cortex, entorhinal cortex, cingulate cortex, mammillary bodies, septum, bed nucleus of stria terminalis, amygdala, and accumbens.
54. The system according to claim 39, wherein the light-activated ion channel and/or the light-activated ion pump protein is at least one of: a channel-rhodopsin (ChR2), and a halorhodopsin (NpHR).
55. The system according to claim 39, wherein the neural tissue is a brain slice.
56. The system according to claim 39, wherein the processor is configured for correlating an activity level of the at least one subfield from the captured image data, and providing processed correlation results useful for assessment of the response of the neural region.
57. The system according to claim 41, wherein the composition for staining the neural tissue comprises the voltage sensitive dye.
58. The system according to claim 39, wherein the stimulator is configured to evoke the cellular electrical response by optically stimulating the neuronal cells.
59. The system according to claim 39, wherein the stimulator is configured to evoke the cellular electrical response by electrically stimulating the neuronal cells.
60. The system according to claim 39, wherein the stimulator is configured to evoke the cellular electrical response by using infrared light.
61. The system according to claim 42, wherein the processor is configured for limiting pixel variations in the image data that are not in the identified areas of interest by median filtering the image data.
62. The system according to claim 61, wherein the processor is configured for median filtering the image data by median filtering with a 3×3 pixel window.
Type: Application
Filed: Jun 12, 2017
Publication Date: Jan 25, 2018
Inventors: Karl Deisseroth (Stanford, CA), Raag D. Airan (Menlo Park, CA), Leslie A. Meltzer (Palo Alto, CA)
Application Number: 15/620,611
